Greenwoods Asset Management Hong Kong Ltd. Bei Gene, Ltd. Transaction History
Greenwoods Asset Management Hong Kong Ltd.
- $2.79 Billion
- Q2 2025
A detailed history of Greenwoods Asset Management Hong Kong Ltd. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Greenwoods Asset Management Hong Kong Ltd. holds 15,502 shares of BGNE stock, worth $3.51 Million. This represents 0.13% of its overall portfolio holdings.
Number of Shares
15,502
Previous 9,329
66.17%
Holding current value
$3.51 Million
Previous $2.11 Million
66.23%
% of portfolio
0.13%
Previous 0.07%
Shares
3 transactions
Others Institutions Holding BGNE
# of Institutions
283Shares Held
32.2MCall Options Held
113KPut Options Held
106K-
Baker Bros. Advisors LP New York, NY8.8MShares$1.99 Billion20.22% of portfolio
-
Primecap Management CO Pasadena, CA5.09MShares$1.15 Billion0.94% of portfolio
-
Capital International Investors Los Angeles, CA4.89MShares$1.11 Billion0.2% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E91.03MShares$234 Million9.68% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.02MShares$231 Million0.03% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $23.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...